A Phase 2 interventional study of Dostarlimab and Pembrolizumab in Lung Cancer, Non-Small Cell, sponsored by GlaxoSmithKline. Terminated at 58 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-08.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline — 1 open to participants now, 7 under way, 3 of them phase 3. Carcinoma, Non-Small-Cell Lung · GlaxoSmithKline.
Among the 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline, this one is the 14th largest by enrollment of the 47 interventional ones that give a count, is one of 3 that started in 2020, is one of 18 in phase 2, and was the 45th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →1 of the 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline is open now, in 12 countries. Recruiting first, the newest first:
Nuvalent Inc. · Sites in United States, Argentina, Australia and 26 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 24 · Phase 3 8
First in 2000; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 243 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 88 across the 47 interventional studies, 1 across the 3 observational. Of the 42 that completed or were terminated, 23 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
1 of the studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02817633Tesaro, Inc.A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
NSCLC comprises of approximately 84 percent (%) of all lung cancers and is often diagnosed at advanced stage due to poor prognosis. Dostarlimab is an immunoglobulin G (IgG)4 kappa humanized monoclonal antibody (mAb) that binds with high affinity to programmed cell death protein 1 (PD 1), resulting in inhibition of binding to programmed death ligand 1 (PD L1) and programmed death ligand 2 (PD L2). This study aims to compare the efficacy and safety PD-1 inhibitors dostarlimab and pembrolizumab, when administered in combination with chemotherapy (pemetrexed, cisplatin and carboplatin), in participants with non-squamous NSCLC without a known sensitizing epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or receptor tyrosine kinase-1 (ROS-1) mutation, BRAF V600E mutation, or other genomic aberration for which an approved targeted therapy is available. A total of approximately 240 participants will be enrolled in the study for a period of 5 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive dostarlimab on Day 1 of every 21 Day cycle followed by pemetrexed, and then followed by cisplatin or carboplatin (Cycles 1 to 4 only) as per investigator decision.
Drug: Dostarlimab · Drug: Chemotherapy
Participants will receive pembrolizumab on Day 1 of every 21 Day cycle followed by pemetrexed, and then followed by cisplatin or carboplatin (Cycles 1 to 4 only) as per investigator decision.
Drug: Pembrolizumab · Drug: Chemotherapy
Dostarlimab will be administered through a 30 minute infusion at a dose of 500 milligrams (mg) intravenously (IV) every 3 weeks (Q3W) up to a maximum of 35 cycles (each cycle of 21 days).
Pembrolizumab will be administered through a 30 minute infusion at a dose of 200 mg Q3W up to a maximum of 35 cycles (each cycle of 21 days).
Pemetrexed will be administered at 500 milligram per meter square (mg/m\^2 ) IV through a 10 minute IV infusion Q3W, up to a maximum of 35 cycles (each cycle of 21 days). Cisplatin will be administered at 75 mg/m\^2 through a 30 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision. Carboplatin will also be administered at area under the concentration time curve 5 milligram/milliliters/minute (mg/mL/min) (maximum dose: 750 mg) through a 15 to 60 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision.
Objective Response Rate (ORR)
ORR was defined as the percentage of participants who had a confirmed complete response (CR) or confirmed partial response (PR) as their best overall response (BOR) recorded from the date of randomization until disease progression or initiation of new anti-cancer therapy, whichever is earlier based on blinded independent central review (BICR) evaluation criteria in solid tumors (RECIST) version 1.1 (v1.1). CR was defined as disappearance of all target lesions. Any pathological lymph nodes must be \<10 millimeter in the short axis. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters (e.g., percent change from baseline).
Time frame: Up to approximately 20 months
Overall Survival (OS)
OS was defined as the time from the date of randomization to the date of death by any cause.
Time frame: Up to approximately 46 months
Progression-free Survival (PFS)
PFS was defined as the time from the date of randomization to the date of disease progression (PD) or death by any cause, whichever occurs first. PFS was evaluated using Response Evaluation Criteria in Solid Tumors Criteria (RECIST) version 1.1 based on Investigator assessment. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start).
Time frame: Up to approximately 46 months
Number of Participants With Treatment-emergent Adverse Event (TEAEs), TEAEs Leading to Death and TEAEs Leading to Treatment Discontinuation
AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is an event that emerges during treatment having been absent pretreatment or worsens relative to the pretreatment state. Number of participants with TEAEs, TEAEs leading to death, and TEAEs leading to treatment discontinuation are presented. AEs were coded using the Medical Dictionary for Regulatory Affairs (MedDRA dictionary).
Time frame: Up to 46 months
Number of Participants With Treatment Emergent Immune-related Adverse Event (irAE)
The irAEs are events which are severe or fatal and can occur in participants treated with monoclonal antibodies directed against immune checkpoints, including pembrolizumab and dostarlimab. While irAEs (eg, diarrhea/colitis, pneumonitis, nephritis, hypophysitis, adrenalitis, thyroiditis, severe skin reactions, uveitis, myocarditis, and hepatotoxicity) usually occur during treatment, symptoms can also manifest after discontinuation of treatment. AEs were coded using the MedDRA dictionary.
Time frame: Up to 46 months
Number of Participants With Serious AEs
An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or is an important medical event that may jeopardize the participant or may require medical or surgical intervention to prevent one of the above outcomes. SAEs are subset of AEs. AEs were coded using the MedDRA dictionary.
Time frame: Up to approximately 46 months
Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline
Normal ranges were 30 to 110 units per liter (U/L) (Amylase); 4. 5 to 5. 6 milligram/deciliters (mg/dL) (Calcium); 96 to 100 milliequivalents (mEq)/ L (Chloride); 2. 5 to 4.5 mg/dL (Phosphate); 6 to 8.3 grams/L (protein); 6 to 24 millimoles/L (Urea) and 7 to 20 mg/dL (Urea nitrogen). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.
Time frame: Up to approximately 46 months
Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline
Normal ranges were 0.01 to 0.3\*10\^9 cells/L (basophils); 41 to 50 percentage of red blood cells (RBC) in blood (hematocrit); 80-100 femtoliters (fl) (erythrocytes \[referred as Ery\] mean corpuscular volume (EMCV)); 2 to 8 percentage of WBC (monocytes); and Women: 4.2 to 5.4 million RBC/ microliter (mcL) of blood and Men: 4.7 to 6.1 million RBC/ mcL (erythrocytes). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.
Time frame: Up to approximately 46 months
Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline
Urine samples were collected to assess urine Bilirubin, glucose, ketones, Leukocyte Esterase, Nitrite, occult blood and Protein using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as No Change/Decreased, Increase to TRACE, Increase to +, Increase to ++, Increase to +++ and Increase to ++++. Baseline (Day 1) was defined as the most recent, non-missing value prior to or on the first study treatment dose date.
Time frame: Up to approximately 46 months
Change From Baseline (CFB) in Thyroid Functions: Free Triiodothyronine (T3) and Free Thyroxine (T4)
Blood samples were collected for the assessment Free Triiodothyronine (T3) and Free Thyroxine (T4).
Time frame: Up to approximately 46 months
Change From Baseline in Thyroid Function: Thyrotropin (TSH)
Blood samples were collected for the assessment of Thyroid Function Thyrotropin (TSH).
Time frame: Up to approximately 46 months
Change From Baseline in Thyroid Functions: Triiodothyronine (T3) and Thyroxine (T4)
Blood samples were collected for the assessment of Triiodothyronine (T3) and Thyroxine (T4).
Time frame: Up to approximately 46 months
Number of Participants With Worst-case Grade Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
DBP and SBP were measured in a semi-supine position after 5 minutes rest. Grades were derived based on numeric criteria as defined in Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Systolic Blood Pressure (SBP): Grade 0 (\<120 Millimetre of mercury (mmHg)), Grade 1 (120-139 mmHg), Grade 2 (140-159 mmHg), Grade 3 (\>=160 mmHg). Diastolic Blood Pressure (DBP): Grade 0 (\<80 mmHg), Grade 1 (80-89 mmHg), Grade 2 (90-99 mmHg), Grade 3 (\>=100 mmHg). An increase is defined as an increase in the CTCAE grade relative to the Baseline grade. Only those participants with grade increase have been presented. Participants with missing Baseline values were assumed to have a Baseline value of G0.
Time frame: Up to approximately 46 months
Number of Participants With Worst Case Pulse Rate Results Post-Baseline Relative to Baseline Based on Potential Clinical Importance (PCI)
Normal range of Pulse Rate was 60 to 100 beats/min. Participants were counted in worst case category that their value changes to low, to within \[w/in\] Range or No Change \[NC\] or high, unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category.
Time frame: Up to approximately 46 months
Number of Participants With Worst-Case Post-Baseline Eastern Cooperative Oncology Group (ECOG) Performance Status
Performance status was assessed using the ECOG scale (Grade 0-5). Grades: 0: Fully active, able to carry on all pre-disease performance without restriction. 1: Restricted in physically strenuous activity but ambulatory, able to carry out work of light nature. 2: Ambulatory, capable of self-care, unable to carry out work activities. Up and about more than 50% waking hours. 3: Capable of limited self-care, confined to bed/chair more than 50% waking hours. 4: Completely disabled. Cannot carry on any self-care. Totally confined to bed/chair. 5: Dead.
Time frame: Up to approximately 46 months
Mean Change From Baseline in Electrocardiogram (ECG) Parameters
Participants were in a supine or semi recumbent position (about 30 degrees of elevation) and rested for approximately 2 minutes before ECGs were recorded. Single 12-lead ECG was recorded using an ECG machine. PR, QRS, QT, QTcF, and RR intervals were recorded
Time frame: Baseline (Day 1), Cycle 1 Day 1, and end of treatment (Up to approximately 46 months)
Mean Change From Baseline in ECG Mean Heart Rate
Participants were in a supine or semi recumbent position (about 30 degrees of elevation) and rested for approximately 2 minutes before ECGs were recorded. Single 12-lead ECG was recorded using an ECG machine. Mean Heart rate were recorded.
Time frame: Baseline (Day 1), Cycle 1 Day 1, and end of treatment (Up to approximately 46 months)
Number Participant Who Used Concomitant Medications
Number of participants received concomitant medications were summarized.
Time frame: Up to approximately 46 months
| Milestone | Dostarlimab + Chemotherapy | Pembrolizumab + Chemotherapy |
|---|---|---|
| Started | 121 | 122 |
| Completed | 81 | 92 |
| Not completed | 40 | 30 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 7 |
| Withdrew: Study terminated by sponsor | 37 | 23 |
OS was defined as the time from the date of randomization to the date of death by any cause.
| Months | Dostarlimab + Chemotherapy | Pembrolizumab + Chemotherapy |
|---|---|---|
| Overall Survival (OS) | 20.2 (14.5 to 27.3) | 15.9 (11.6 to 19.3) |
PFS was defined as the time from the date of randomization to the date of disease progression (PD) or death by any cause, whichever occurs first. PFS was evaluated using Response Evaluation Criteria in Solid Tumors Criteria (RECIST) version 1.1 based on Investigator assessment. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start).
| Months | Dostarlimab + Chemotherapy | Pembrolizumab + Chemotherapy |
|---|---|---|
| Progression-free Survival (PFS) | 8.8 (6.9 to 11.0) | 6.8 (4.9 to 7.1) |
AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is an event that emerges during treatment having been absent pretreatment or worsens relative to the pretreatment state. Number of participants with TEAEs, TEAEs leading to death, and TEAEs leading to treatment discontinuation are presented. AEs were coded using the Medical Dictionary for Regulatory Affairs (MedDRA dictionary).
| Participants | Dostarlimab + Chemotherapy | Pembrolizumab + Chemotherapy |
|---|---|---|
| TEAEs | 119 | 119 |
| TEAEs leading to death | 17 | 12 |
| TEAEs leading to treatment discontinuation | 35 | 46 |
The irAEs are events which are severe or fatal and can occur in participants treated with monoclonal antibodies directed against immune checkpoints, including pembrolizumab and dostarlimab. While irAEs (eg, diarrhea/colitis, pneumonitis, nephritis, hypophysitis, adrenalitis, thyroiditis, severe skin reactions, uveitis, myocarditis, and hepatotoxicity) usually occur during treatment, symptoms can also manifest after discontinuation of treatment. AEs were coded using the MedDRA dictionary.
| Participants | Dostarlimab + Chemotherapy | Pembrolizumab + Chemotherapy |
|---|---|---|
| Number of Participants With Treatment Emergent Immune-related Adverse Event (irAE) | 38 | 47 |
An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or is an important medical event that may jeopardize the participant or may require medical or surgical intervention to prevent one of the above outcomes. SAEs are subset of AEs. AEs were coded using the MedDRA dictionary.
| Participants | Dostarlimab + Chemotherapy | Pembrolizumab + Chemotherapy |
|---|---|---|
| Number of Participants With Serious AEs | 51 | 61 |
Normal ranges were 30 to 110 units per liter (U/L) (Amylase); 4. 5 to 5. 6 milligram/deciliters (mg/dL) (Calcium); 96 to 100 milliequivalents (mEq)/ L (Chloride); 2. 5 to 4.5 mg/dL (Phosphate); 6 to 8.3 grams/L (protein); 6 to 24 millimoles/L (Urea) and 7 to 20 mg/dL (Urea nitrogen). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.
| Participants | Dostarlimab + Chemotherapy | Pembrolizumab + Chemotherapy |
|---|---|---|
| Amylase, To Low | 8 | 11 |
| Amylase, To Normal or No Change | 76 | 76 |
| Amylase, To High | 34 | 30 |
| Calcium, To Low | 42 | 39 |
| Calcium, To Normal or No Change | 60 | 65 |
| Calcium, To High | 25 | 16 |
| Chloride, To Low | 34 | 26 |
| Chloride, To Normal or No Change | 65 | 69 |
| Chloride, To High | 22 | 25 |
| Phosphate, To Low | 32 | 22 |
| Phosphate, To Normal or No Change | 64 | 70 |
| Phosphate, To High | 26 | 28 |
| Protein, To Low | 52 | 54 |
| Protein, To Normal or No Change | 55 | 56 |
| Protein, To High | 12 | 6 |
| Urea, To Low | 7 | 11 |
| Urea, To Normal or No Change | 43 | 45 |
| Urea, To High | 41 | 37 |
| Urea Nitrogen, To Low | 5 | 6 |
| Urea Nitrogen, To Normal or No Change | 26 | 17 |
| Urea Nitrogen, To High | 20 | 13 |
Normal ranges were 0.01 to 0.3\*10\^9 cells/L (basophils); 41 to 50 percentage of red blood cells (RBC) in blood (hematocrit); 80-100 femtoliters (fl) (erythrocytes \[referred as Ery\] mean corpuscular volume (EMCV)); 2 to 8 percentage of WBC (monocytes); and Women: 4.2 to 5.4 million RBC/ microliter (mcL) of blood and Men: 4.7 to 6.1 million RBC/ mcL (erythrocytes). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.
| Participants | Dostarlimab + Chemotherapy | Pembrolizumab + Chemotherapy |
|---|---|---|
| Basophils, To Low | 12 | 9 |
| Basophils, To Normal or No Change | 72 | 75 |
| Basophils, To High | 19 | 19 |
| Hematocrit, To Low | 73 | 64 |
| Hematocrit, To Normal or No Change | 43 | 50 |
| Hematocrit, To High | 3 | 1 |
| EMCV, To Low | 6 | 11 |
| EMCV, To Normal or No Change | 59 | 54 |
| EMCV, To High | 57 | 54 |
| Monocytes, To Low | 23 | 21 |
| Monocytes, To Normal or No Change | 41 | 42 |
| Monocytes, To High | 46 | 43 |
| Erythrocytes, To Low | 73 | 79 |
| Erythrocytes, To Normal or No Change | 44 | 34 |
| Erythrocytes, To High | 2 | 6 |
Urine samples were collected to assess urine Bilirubin, glucose, ketones, Leukocyte Esterase, Nitrite, occult blood and Protein using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as No Change/Decreased, Increase to TRACE, Increase to +, Increase to ++, Increase to +++ and Increase to ++++. Baseline (Day 1) was defined as the most recent, non-missing value prior to or on the first study treatment dose date.
| Participants | Dostarlimab + Chemotherapy | Pembrolizumab + Chemotherapy |
|---|---|---|
| Bilirubin, No Change/Decreased | 86 | 66 |
| Bilirubin, Increase to TRACE | 0 | 0 |
| Bilirubin, Increase to + | 4 | 3 |
| Bilirubin, Increase to ++ | 0 | 0 |
| Bilirubin, Increase to +++ | 0 | 0 |
| Bilirubin, Increase to ++++ | 0 | 0 |
| Glucose, No Change/Decreased | 79 | 57 |
| Glucose, Increase to TRACE | 2 | 1 |
| Glucose, Increase to + | 8 | 8 |
| Glucose, Increase to ++ | 1 | 2 |
| Glucose, Increase to +++ | 1 | 2 |
| Glucose, Increase to ++++ | 2 | 1 |
| Ketones, No Change/Decreased | 81 | 58 |
| Ketones, Increase to TRACE | 4 | 3 |
| Ketones, Increase to + | 8 | 7 |
| Ketones, Increase to ++ | 0 | 2 |
| Ketones, Increase to +++ | 0 | 1 |
| Ketones, Increase to ++++ | 0 | 0 |
| Leukocyte Esterase, No Change/Decreased | 75 | 55 |
| Leukocyte Esterase, Increase to TRACE | 1 | 2 |
| Leukocyte Esterase, Increase to + | 11 | 10 |
| Leukocyte Esterase, Increase to ++ | 2 | 0 |
| Leukocyte Esterase, Increase to +++ | 1 | 3 |
| Leukocyte Esterase, Increase to ++++ | 1 | 0 |
| Nitrite, No Change/Decreased | 90 | 70 |
| Nitrite, Increase to TRACE | 0 | 0 |
| Nitrite, Increase to + | 3 | 1 |
| Nitrite, Increase to ++ | 0 | 0 |
| Nitrite, Increase to +++ | 0 | 0 |
| Nitrite, Increase to ++++ | 0 | 0 |
| Occult Blood, No Change/Decreased | 77 | 57 |
| Occult Blood, Increase to TRACE | 6 | 3 |
| Occult Blood, Increase to + | 6 | 8 |
| Occult Blood, Increase to ++ | 3 | 3 |
| Occult Blood, Increase to +++ | 0 | 0 |
| Occult Blood, Increase to ++++ | 0 | 0 |
| Protein, No Change/Decreased | 71 | 53 |
| Protein, Increase to TRACE | 7 | 3 |
| Protein, Increase to + | 14 | 10 |
| Protein, Increase to ++ | 0 | 3 |
| Protein, Increase to +++ | 1 | 1 |
| Protein, Increase to ++++ | 0 | 0 |
Blood samples were collected for the assessment Free Triiodothyronine (T3) and Free Thyroxine (T4).
| Picomoles per liter(pmol/L) | Dostarlimab + Chemotherapy | Pembrolizumab + Chemotherapy |
|---|---|---|
| Triiodothyronine, Free, Baseline | 4.48026 ± 1.638746 | 4.48540 ± 1.066597 |
| Triiodothyronine, Free, CFB to Cycle 2 Day 1 | -0.12423 ± 2.071042 | -0.24330 ± 1.026993 |
| Triiodothyronine, Free, CFB to Cycle 4 Day 1 | -0.00187 ± 2.206972 | -0.11796 ± 1.413190 |
| Triiodothyronine, Free, CFB to Cycle 6 Day 1 | -0.15030 ± 2.128584 | -0.37705 ± 1.117516 |
| Triiodothyronine, Free, CFB to Cycle 8 Day 1 | 0.11483 ± 2.738875 | -0.43073 ± 1.123017 |
| Triiodothyronine, Free, CFB to Cycle 10 Day 1 | -0.25993 ± 2.187046 | -0.23819 ± 1.273369 |
| Triiodothyronine, Free, CFB to Cycle 12 Day 1 | -0.04347 ± 2.817465 | 5.82171 ± 34.328615 |
| Triiodothyronine, Free, CFB to Cycle 14 Day 1 | -0.61895 ± 2.558169 | -0.33501 ± 1.597219 |
| Triiodothyronine, Free, CFB to Cycle 16 Day 1 | -0.44645 ± 2.274173 | -0.36614 ± 1.108135 |
| Triiodothyronine, Free, CFB to Cycle 18 Day 1 | -0.37234 ± 2.414983 | -0.12607 ± 1.337185 |
| Triiodothyronine, Free, CFB to Cycle 20 Day 1 | -0.37506 ± 2.495642 | -0.26936 ± 1.237097 |
| Triiodothyronine, Free, CFB to Cycle 22 Day 1 | -0.36400 ± 2.759103 | -0.17980 ± 1.018812 |
| Triiodothyronine, Free, CFB to Cycle 24 Day 1 | -0.69144 ± 2.662922 | -0.18380 ± 0.736262 |
| Triiodothyronine, Free, CFB to Cycle 26 Day 1 | 0.01392 ± 1.331466 | -0.39401 ± 0.669173 |
| Triiodothyronine, Free, CFB to Cycle 28 Day 1 | -0.05502 ± 1.094085 | -0.28233 ± 0.880805 |
| Triiodothyronine, Free, CFB to Cycle 30 Day 1 | 0.11929 ± 1.151771 | -0.19119 ± 0.911551 |
| Triiodothyronine, Free, CFB to Cycle 32 Day 1 | 0.54114 ± 1.043916 | 0.03556 ± 1.067239 |
| Triiodothyronine, Free, CFB to Cycle 34 Day 1 | 0.62534 ± 0.957105 | -0.32236 ± 0.774334 |
| Triiodothyronine, Free, CFB to End of Treatment | -0.64275 ± 2.184114 | -0.40528 ± 1.086922 |
| Thyroxine, Free, Baseline | 16.33405 ± 4.294246 | 15.93013 ± 3.436512 |
| Thyroxine, Free, CFB to Cycle 2 Day 1 | -0.35227 ± 4.257866 | 0.21349 ± 3.541952 |
| Thyroxine, Free, CFB to Cycle 4 Day 1 | 0.04265 ± 6.245167 | 0.08969 ± 4.015042 |
| Thyroxine, Free, CFB to Cycle 6 Day 1 | -0.10229 ± 5.418010 | -0.58695 ± 3.404576 |
| Thyroxine, Free, CFB to Cycle 8 Day 1 | -1.02504 ± 6.168755 | 0.27944 ± 3.877876 |
| Thyroxine, Free, CFB to Cycle 10 Day 1 | -1.15108 ± 5.586383 | 0.08349 ± 3.613602 |
| Thyroxine, Free, CFB to Cycle 12 Day 1 | -0.16670 ± 6.081753 | 4.71828 ± 27.489015 |
| Thyroxine, Free, CFB to Cycle 14 Day 1 | 0.32703 ± 6.114475 | -0.45213 ± 4.196576 |
| Thyroxine, Free, CFB to Cycle 16 Day 1 | -0.45337 ± 4.840440 | 0.24537 ± 3.472618 |
| Thyroxine, Free, CFB to Cycle 18 Day 1 | 0.07645 ± 5.524789 | 0.47690 ± 1.984139 |
| Thyroxine, Free, CFB to Cycle 20 Day 1 | -0.41084 ± 5.013270 | 0.37830 ± 3.413511 |
| Thyroxine, Free, CFB to Cycle 22 Day 1 | -0.65956 ± 5.562802 | 0.45462 ± 2.841910 |
| Thyroxine, Free, CFB to Cycle 24 Day 1 | -0.71092 ± 6.314352 | 0.31032 ± 2.653193 |
| Thyroxine, Free, CFB to Cycle 26 Day 1 | -0.89968 ± 5.246300 | 0.23139 ± 3.443957 |
| Thyroxine, Free, CFB to Cycle 28 Day 1 | -0.89658 ± 5.489130 | 1.10907 ± 2.849631 |
| Thyroxine, Free, CFB to Cycle 30 Day 1 | -1.46126 ± 4.811596 | -0.21286 ± 3.203649 |
| Thyroxine, Free, CFB to Cycle 32 Day 1 | -1.81377 ± 5.474197 | 0.13236 ± 3.519557 |
| Thyroxine, Free, CFB to Cycle 34 Day 1 | -1.52641 ± 6.379163 | 0.45041 ± 2.435328 |
| Thyroxine, Free, CFB to End of Treatment | 0.26660 ± 3.882315 | 0.46964 ± 3.310829 |
Blood samples were collected for the assessment of Thyroid Function Thyrotropin (TSH).
| Milli-international Units/ Liter | Dostarlimab + Chemotherapy | Pembrolizumab + Chemotherapy |
|---|---|---|
| Baseline | 1.853 ± 1.8354 | 1.904 ± 1.7421 |
| CFB to Cycle 2 Day 1 | 0.225 ± 3.7642 | -0.497 ± 1.7405 |
| CFB to Cycle 4 Day 1 | 1.285 ± 9.4283 | -0.622 ± 1.7892 |
| CFB to Cycle 6 Day 1 | 1.123 ± 8.4596 | 2.006 ± 21.0213 |
| CFB to Cycle 8 Day 1 | 2.454 ± 9.7235 | 2.648 ± 22.9952 |
| CFB to Cycle 10 Day 1 | 3.233 ± 12.1571 | 1.986 ± 12.8377 |
| CFB to Cycle 12 Day 1 | 2.448 ± 9.8590 | 1.138 ± 10.9780 |
| CFB to Cycle 14 Day 1 | 1.282 ± 4.2566 | 1.734 ± 9.0539 |
| CFB to Cycle 16 Day 1 | 1.551 ± 4.7982 | 2.056 ± 13.4532 |
| CFB to Cycle 18 Day 1 | 1.190 ± 4.1837 | -0.406 ± 1.6364 |
| CFB to Cycle 20 Day 1 | 1.685 ± 5.3517 | 1.825 ± 11.8029 |
| CFB to Cycle 22 Day 1 | 1.428 ± 5.9512 | 1.794 ± 10.5658 |
| CFB to Cycle 24 Day 1 | 0.993 ± 3.0372 | 2.161 ± 10.7015 |
| CFB to Cycle 26 Day 1 | 1.029 ± 4.3080 | 2.050 ± 11.8067 |
| CFB to Cycle 28 Day 1 | 1.204 ± 3.4902 | 1.760 ± 9.6622 |
| CFB to Cycle 30 Day 1 | 1.615 ± 5.4966 | 3.468 ± 15.7231 |
| CFB to Cycle 32 Day 1 | 1.824 ± 4.9423 | 0.365 ± 0.8151 |
| CFB to Cycle 34 Day 1 | 1.081 ± 2.4504 | -0.189 ± 1.5062 |
| CFB to End of Treatment | 2.210 ± 8.3867 | 1.303 ± 9.3590 |
Blood samples were collected for the assessment of Triiodothyronine (T3) and Thyroxine (T4).
| Nanomoles per liter (nmol/L) | Dostarlimab + Chemotherapy | Pembrolizumab + Chemotherapy |
|---|---|---|
| Triiodothyronine, Baseline | 1.68399 ± 0.308404 | 1.48287 ± 0.526037 |
| Triiodothyronine, CFB to Cycle 2 Day 1 | 0.06903 ± 0.172873 | -0.58292 |
| Triiodothyronine, CFB to Cycle 4 Day 1 | -0.41878 ± 0.353613 | — |
| Triiodothyronine, CFB to Cycle 6 Day 1 | -0.21476 | — |
| Thyroxine, Baseline | 72.72912 ± 46.845564 | 85.29069 ± 38.027652 |
| Thyroxine, CFB to Cycle 2 Day 1 | 16.06393 ± 38.489073 | -3.12689 ± 11.544100 |
| Thyroxine, CFB to Cycle 4 Day 1 | 10.16002 ± 47.746764 | 12.22592 ± 30.578995 |
| Thyroxine, CFB to Cycle 6 Day 1 | 9.83083 ± 30.658114 | -2.45916 ± 27.497527 |
| Thyroxine, CFB to Cycle 8 Day 1 | 21.85010 ± 44.242770 | -0.06812 ± 24.146111 |
| Thyroxine, CFB to Cycle 10 Day 1 | 32.19186 ± 41.441071 | -0.03002 ± 16.413851 |
| Thyroxine, CFB to Cycle 12 Day 1 | 23.45510 ± 36.165686 | -0.82919 ± 9.539787 |
| Thyroxine, CFB to Cycle 14 Day 1 | 14.79794 ± 35.614508 | 0.64908 ± 12.623292 |
| Thyroxine, CFB to Cycle 16 Day 1 | 21.23230 ± 38.220665 | 7.86174 ± 18.910608 |
| Thyroxine, CFB to Cycle 18 Day 1 | 18.35801 ± 31.436316 | 7.37470 ± 8.635752 |
| Thyroxine, CFB to Cycle 20 Day 1 | 26.94600 ± 47.915257 | 16.06215 ± 18.656008 |
| Thyroxine, CFB to Cycle 22 Day 1 | 22.73866 ± 34.202890 | 18.57057 ± 22.383758 |
| Thyroxine, CFB to Cycle 24 Day 1 | 24.31027 ± 45.963345 | 23.08569 ± 20.160509 |
| Thyroxine, CFB to Cycle 26 Day 1 | 32.22436 ± 62.122105 | 35.71425 ± 12.285627 |
| Thyroxine, CFB to Cycle 28 Day 1 | 21.13316 ± 46.351292 | 20.55189 ± 17.985775 |
| Thyroxine, CFB to Cycle 30 Day 1 | 19.12904 ± 53.351526 | 13.09008 ± 11.862148 |
| Thyroxine, CFB to Cycle 32 Day 1 | 19.99271 ± 58.500079 | 16.73184 ± 23.660023 |
| Thyroxine, CFB to Cycle 34 Day 1 | -4.97280 ± 8.622499 | 0.01300 |
| Thyroxine, CFB to End of Treatment | 11.06954 ± 35.792455 | 4.67311 ± 29.791225 |
DBP and SBP were measured in a semi-supine position after 5 minutes rest. Grades were derived based on numeric criteria as defined in Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Systolic Blood Pressure (SBP): Grade 0 (\<120 Millimetre of mercury (mmHg)), Grade 1 (120-139 mmHg), Grade 2 (140-159 mmHg), Grade 3 (\>=160 mmHg). Diastolic Blood Pressure (DBP): Grade 0 (\<80 mmHg), Grade 1 (80-89 mmHg), Grade 2 (90-99 mmHg), Grade 3 (\>=100 mmHg). An increase is defined as an increase in the CTCAE grade relative to the Baseline grade. Only those participants with grade increase have been presented. Participants with missing Baseline values were assumed to have a Baseline value of G0.
| Participants | Dostarlimab + Chemotherapy | Pembrolizumab + Chemotherapy |
|---|---|---|
| DBP, Increase to Grade 1 | 36 | 27 |
| DBP, Increase to Grade 2 | 35 | 25 |
| DBP, Increase to Grade 3 | 6 | 7 |
| SBP, Increase to Grade 1 | 24 | 18 |
| SBP, Increase to Grade 2 | 34 | 24 |
| SBP, Increase to Grade 3 | 8 | 11 |
Normal range of Pulse Rate was 60 to 100 beats/min. Participants were counted in worst case category that their value changes to low, to within \[w/in\] Range or No Change \[NC\] or high, unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in "To Normal or No Change" category.
| Participants | Dostarlimab + Chemotherapy | Pembrolizumab + Chemotherapy |
|---|---|---|
| To Low | 5 | 3 |
| To w/in Range or No Change | 105 | 103 |
| To High | 7 | 9 |
Performance status was assessed using the ECOG scale (Grade 0-5). Grades: 0: Fully active, able to carry on all pre-disease performance without restriction. 1: Restricted in physically strenuous activity but ambulatory, able to carry out work of light nature. 2: Ambulatory, capable of self-care, unable to carry out work activities. Up and about more than 50% waking hours. 3: Capable of limited self-care, confined to bed/chair more than 50% waking hours. 4: Completely disabled. Cannot carry on any self-care. Totally confined to bed/chair. 5: Dead.
| Participants | Dostarlimab + Chemotherapy | Pembrolizumab + Chemotherapy |
|---|---|---|
| 0 | 15 | 20 |
| 1 | 70 | 57 |
| 2 | 24 | 20 |
| 3 | 4 | 14 |
| 4-5 | 5 | 4 |
Participants were in a supine or semi recumbent position (about 30 degrees of elevation) and rested for approximately 2 minutes before ECGs were recorded. Single 12-lead ECG was recorded using an ECG machine. PR, QRS, QT, QTcF, and RR intervals were recorded
| Millisecond (msec) | Dostarlimab + Chemotherapy | Pembrolizumab + Chemotherapy |
|---|---|---|
| PR Interval, Baseline | 157.3 ± 26.87 | 152.4 ± 25.54 |
| PR Interval, CFB to Cycle 1 Day 1 | -6.0 ± 1.41 | 8.7 ± 16.17 |
| PR Interval, CFB to End of Treatment | -5.3 ± 23.35 | 0.2 ± 17.49 |
| QRS Duration, Baseline | 87.9 ± 14.85 | 89.0 ± 14.91 |
| QRS Duration, CFB to Cycle 1 Day 1 | 10.0 ± 13.08 | 6.0 ± 14.14 |
| QRS Duration, CFB to End of Treatment | 3.3 ± 17.14 | -1.1 ± 13.47 |
| QT Interval, Baseline | 370.4 ± 35.29 | 374.3 ± 38.05 |
| QT Interval, CFB to Cycle 1 Day 1 | -19.5 ± 48.23 | -27.3 ± 57.98 |
| QT Interval, CFB to End of Treatment | -1.7 ± 36.57 | -4.1 ± 38.07 |
| QTcB Interval, Baseline | 459.3 ± 190.83 | 440.4 ± 121.20 |
| QTcB Interval, CFB to Cycle 1 Day 1 | -309.0 ± 559.52 | -31.7 ± 49.81 |
| QTcB Interval, CFB to End of Treatment | -12.2 ± 176.21 | -3.1 ± 30.81 |
| QTcF Interval, Baseline | 406.6 ± 50.60 | 412.9 ± 48.99 |
| QTcF Interval, CFB to Cycle 1 Day 1 | -12.3 ± 48.19 | -4.7 ± 4.16 |
| QTcF Interval, CFB to End of Treatment | 1.4 ± 65.82 | -10.0 ± 60.00 |
| RR Interval, Baseline | 741.3 ± 205.25 | 766.5 ± 195.43 |
| RR Interval, CFB to Cycle 1 Day 1 | 81.3 ± 256.20 | -10.7 ± 81.05 |
| RR Interval, CFB to End of Treatment | -3.3 ± 183.71 | 2.5 ± 193.04 |
Participants were in a supine or semi recumbent position (about 30 degrees of elevation) and rested for approximately 2 minutes before ECGs were recorded. Single 12-lead ECG was recorded using an ECG machine. Mean Heart rate were recorded.
| beats/min | Dostarlimab + Chemotherapy | Pembrolizumab + Chemotherapy |
|---|---|---|
| Baseline | 79.8 ± 15.17 | 80.0 ± 16.14 |
| CFB to Cycle 1 Day 1 | 0.0 ± 13.04 | 3.3 ± 13.65 |
| CFB to End of Treatment | 1.5 ± 14.71 | 0.6 ± 17.95 |
Number of participants received concomitant medications were summarized.
| Participants | Dostarlimab + Chemotherapy | Pembrolizumab + Chemotherapy |
|---|---|---|
| Number Participant Who Used Concomitant Medications | 121 | 122 |
ORR was defined as the percentage of participants who had a confirmed complete response (CR) or confirmed partial response (PR) as their best overall response (BOR) recorded from the date of randomization until disease progression or initiation of new anti-cancer therapy, whichever is earlier based on blinded independent central review (BICR) evaluation criteria in solid tumors (RECIST) version 1.1 (v1.1). CR was defined as disappearance of all target lesions. Any pathological lymph nodes must be \<10 millimeter in the short axis. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters (e.g., percent change from baseline).
| Percentage of Participants | Dostarlimab + Chemotherapy | Pembrolizumab + Chemotherapy |
|---|---|---|
| Objective Response Rate (ORR) | 46 (37.2 to 55.6) | 37 (28.3 to 46.1) |
Collected over All cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected from Day 1 and up to approximately 46 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dostarlimab + Chemotherapy | 80/121 (66.1%) | 51/121 (42.1%) | 117/121 (96.7%) |
| Pembrolizumab + Chemotherapy | 91/122 (74.6%) | 61/122 (50%) | 114/122 (93.4%) |
| Event | Dostarlimab + Chemotherapy | Pembrolizumab + Chemotherapy |
|---|---|---|
| PneumoniaInfections and infestations | 4/121 | 15/122 |
| AnaemiaBlood and lymphatic system disorders | 9/121 | 6/122 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/121 | 4/122 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 3/121 | 5/122 |
| Febrile neutropeniaBlood and lymphatic system disorders | 4/121 | 4/122 |
| COVID-19Infections and infestations | 4/121 | 3/122 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 4/121 | 1/122 |
| PyrexiaGeneral disorders | 1/121 | 4/122 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/121 | 3/122 |
| AstheniaGeneral disorders | 3/121 | 1/122 |
| Event | Dostarlimab + Chemotherapy | Pembrolizumab + Chemotherapy |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 63/121 | 59/122 |
| AstheniaGeneral disorders | 41/121 | 42/122 |
| NauseaGastrointestinal disorders | 31/121 | 32/122 |
| CoughRespiratory, thoracic and mediastinal disorders | 26/121 | 22/122 |
| ConstipationGastrointestinal disorders | 24/121 | 26/122 |
| VomitingGastrointestinal disorders | 25/121 | 16/122 |
| NeutropeniaBlood and lymphatic system disorders | 22/121 | 25/122 |
| Decreased appetiteMetabolism and nutrition disorders | 24/121 | 20/122 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 22/121 | 21/122 |
| DiarrhoeaGastrointestinal disorders | 21/121 | 17/122 |
| Age, Continuous(YEARS) | Dostarlimab + Chemotherapy | Pembrolizumab + Chemotherapy | Total |
|---|---|---|---|
| Mean | 63.4 ± 9.43 | 65.4 ± 8.51 | 64.4 ± 9.02 |
| Sex: Female, Male(Participants) | Dostarlimab + Chemotherapy | Pembrolizumab + Chemotherapy | Total |
|---|---|---|---|
| Female | 36 | 45 | 81 |
| Male | 85 | 77 | 162 |
| Race/Ethnicity, Customized(Participants) | Dostarlimab + Chemotherapy | Pembrolizumab + Chemotherapy | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 23 | 21 | 44 |
| Black or African American | 1 | 3 | 4 |
| White | 87 | 84 | 171 |
| Multiple | 3 | 3 | 6 |
| Not Reported | 2 | 5 | 7 |
| Unknown | 4 | 6 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Nov 2020 to primary completion in Aug 2022, 20 months.
Results were first posted in Sep 2023, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dostarlimab
Carcinoma, Non-Small-Cell Lung →